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• In 2002, when results of the Women's Health Initiative (WHI) 
randomised controlled trial of hormone replacement therapy 
(HRT) showed an increased occurrence of breast cancer and 
thromboembolism, up to two-thirds of women taking HRT 
stopped the therapy, often without medical consultation.
• Recent analyses of the WHI data and other randomised 
controlled trials suggest that, although there are potential 
side effects and risks involved in taking HRT, these may be 
reduced by:
? using lower HRT doses;
? minimising or eliminating systemic progestogens;
? using non-oral routes in some women; and
? initiating HRT in symptomatic women near menopause.
• When HRT is initiated near menopause for symptom control, 
there may be additional benefits (reduced fracture and 
cardiovascular risk) that outweigh the risks (which are not 
significantly raised in women under age 60 years).
• Older women with continuing symptoms should not be 
denied HRT if their therapy and risks are assessed on an 
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individual basis and each patient is aware of the risks.efo
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meB re 2002, observational studies (Level III-2 and Level III-3idence, see Box 11) were mostly of women who com-nced hormone replacement therapy (HRT) for symptom
control near menopause. These studies suggested that taking long-
term HRT reduced cardiovascular and fracture risk, but increased
the risk of breast cancer and thromboembolism. In 2002, the
initial results of a long-term randomised controlled trial (Level II)
of HRT (Women’s Health Initiative [WHI]) showed that, after 5








bodies rather too quickly issued edicts, based on the WHI report,
saying that HRT should only be used at the lowest dose for the
shortest possible time in women with severe symptoms.4
Recent analyses of the WHI data, other randomised controlled
trials, and observational and animal studies have now unified
much of the data on HRT and greatly changed the risk–benefit
ratio for most women who commence HRT for symptom control
around menopause. It is mostly good news (Box 2).
Cardiovascular disease
There are now strong data in support of the “critical therapeutic
window” hypothesis that oestrogen is cardioprotective if initiated
around menopause when there are still vascular oestrogen recep-
tors responsive to exogenous HRT.5-7 HRT administered near
menopause appears to reduce the progression of atherosclerotic
plaque, but if administered many years after menopause it is not
beneficial and may sometimes disrupt established plaque with
adverse outcomes.
A meta-analysis of randomised trials (Level I) has shown a
statistically and clinically significant 39% reduction in cardiac
events in the treatment groups, compared with the placebo control
groups, when HRT is initiated in women under 60 years of age
(odds ratio [OR], 0.68; 95% CI, 0.48–0.96), but this cardioprotec-
tive effect was not seen in women starting HRT after age 60 years
(OR, 1.03; 95% CI, 0.91–1.16).8 When HRT is first taken many
years after menopause, there is an increase in cardiac events during
the first year of therapy (hazard ratio [HR], 1.47; 95% CI, 1.12–
1.92).8 Subsequent cardiac morbidity is reduced after taking HRT
for 2 years in these older women (HR, 0.79; 95% CI, 0.67–0.93).8
All-cause mortality in younger HRT users compared with placebo
is also significantly reduced (HR, 0.61; 95% CI, 0.39–0.95).9
Currently, data from Level II trials in women near menopause
suggest that oestrogen-only regimens may offer greater cardiopro-
tection than some combined regimens, but more research is
needed on the timing and type of progestogen therapy in com-
bined regimens.7,10
The two long-term Level II trials of HRT (WHI and WISDOM –
Women’s International Study of long Duration Oestrogen after
Menopause) enrolled women who were on average 13–14 years
post-menopause, because the outcomes being measured are more
prevalent at older ages. The populations in these trials were
unrepresentative of symptomatic women who start taking HRT
near menopause. Although the WHI alone did not have sufficient
power to allow subanalyses of cardiac events in the 8832 women
under age 60 years in the two HRT trial arms, data from the WHI
now suggest a cardioprotective effect in women commencing HRT
near menopause, especially when oestrogen-only regimens are
1 National Health and Medical Research Council levels of 
evidence1
I Evidence obtained from a systematic review of all relevant 
randomised controlled trials.
II Evidence obtained from at least one properly designed 
randomised controlled trial.
III-1 Evidence obtained from well designed pseudo-randomised 
controlled trials (alternate allocation or some other method).
III-2 Evidence obtained from comparative studies with concurrent 
controls and allocation not randomised (cohort studies), case–
control analytic studies, or interrupted time series with a control 
group.
III-3 Evidence obtained from comparative studies with historical 
control, two or more single-arm studies, or interrupted time 
series without a parallel control group.
IV Evidence obtained from case series, either post-test or pre-test 
and post-test.  ◆ber 12 • 18 June 2007 643
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Breast cancer
Before the WHI, observational studies (Level III-2 and Level III-3)
had suggested an increased relative risk of breast cancer with long-
term combined HRT (cHRT) of 1.53 after a median of 8 years.11
The WHI actually reported half this risk, with a relative risk after
5.6 years of cHRT of 1.26 (adjusted 95% CI, 0.83–1.92).2
However, media reports often highlighted the relative risk without
explaining the absolute risk. The absolute increased risk found in
the WHI was 8 per 10 000 women-years, or less than 0.1% per
annum. Systematic reviews of all the Level II and III-2 data now
suggest that, in women taking combined HRT, there is an
increased risk of breast cancer of 4 per 10 000 women-years, or 2
per 1000 women after 5 years.12-14 Some groups have preferred to
use worst-case scenario statistics derived from observational data,
including the Million Women Study (Level III-3).15 Observational
data may increase the real risk and benefits (due to selection and
detection biases), whereas intention-to-treat analyses of ran-
domised controlled trials may reduce the real risk and benefits
attributable to the therapy if non-compliance rates are high. Both
methods have their merits and demerits, but Level II evidence is
usually regarded as stronger evidence than Level III-2 evidence!
Another way to look at risk is to compare the increased relative
risk (RR) of breast cancer found in the WHI (1.26) with other
common risks. Thus, this relative risk is similar to the breast
cancer risk in a woman with late menopause at age 55 or more
(RR, 1.22); in a woman who has three alcoholic drinks per day
(RR, 1.4); or in a nulliparous woman (RR, 1.67).16 Subsequent
analysis of the WHI data showed that there was no significant
increase in breast cancer among those who initiated cHRT for the
first time during the 7 years of the WHI.17
Even better news from the WHI in relation to breast cancer came
when outcomes of the oestrogen-only arm in women who had had
a hysterectomy showed an almost statistically significant reduction
in breast cancer (HR, 0.77; 95% CI, 0.59–1.01).18 These results
challenge many of the beliefs about oestrogen and breast cancer,
but may incriminate use of systemic progestogen. Data on regi-
mens that avoid the undoubted risk of long-term cHRT (eg,
tibolone or intrauterine progestogen and systemic oestrogen) are
awaited. Observational data (Level III-3) have suggested that more
than 20 years of oestrogen-only therapy may increase breast cancer
rates.19
Thromboembolism
Thromboembolism remains the main short-term serious risk of
taking HRT. The risk of thromboembolism in women taking oral
HRT appears to be greatest in the first year or two of use and is
highest in those with thrombophilia and/or obesity.20 The absolute
risk varies with the individual risk for thromboembolism. The risk
increases with age at initiation of HRT.20 In the future, general
screening for thrombophilia may become a cost-effective proposi-
tion; currently, screening women with clinical risk factors for
thromboembolism may be justified. Non-oral routes of oestrogen
intake, adding micronised progesterone, or pregnane-derived pro-
gestogens in women with an intact uterus have not been associated
with thromboembolic risk (Level III-2), but no long-term ran-
domised trials have been performed.21
Fractures
The expected one-third reduction in fractures (hip, spine and
overall) seen in observational studies was confirmed by the WHI
(cHRT — HR, 0.76; 95% CI, 0.69–0.92; oestrogen replacement
therapy — HR, 0.70; 95% CI, 0.59–0.83).2,18 Importantly, this
reduction was seen in a population not screened for osteoporosis.
HRT remains a cost-efficient and relatively safe option for the
prevention of fractures when initiated before age 60 years in
women with osteoporosis, who often also have menopausal symp-
toms.22,23 Such women may have few other cost-efficient thera-
peutic options, and this indication for HRT needs to be revisited
now the risks of HRT (especially low-dose, oestrogen-only regi-
mens) have been recalculated.
Cognitive function and dementia
The effect of HRT on cognitive function is likely to remain
controversial because a long-term trial from the time of menopause
will probably be impossible. Observational studies (Level III-2)
2 The main increased and decreased morbidities 
reported in the combined oestrogen and progestin 
arm and the oestrogen-only arm of the Women’s 
Health Initiative (WHI) trial, compared with placebo, 
per 10 000 women-years
A: After 5 years of combined hormone replacement therapy (HRT).
B: After 7 years of oestrogen-only HRT. 
C: Oestrogen-only HRT initiated at age 50–59 years.
Complete data for women under age 60 years in the WHI have only been 
published for the oestrogen-only arm. The WHI was not powered for such 
subanalyses, as major morbidities are uncommon in this age group.
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VIEWPOINTsupport the critical therapeutic window hypothesis in which HRT
use from near menopause shows greater benefit for cognitive
function than commencing HRT many years after menopause.24
Among women in the WHI trial who commenced HRT when over
65 years of age, a slight detriment in cognitive function was found
in this older group.25 The Cache County observational study noted
a 59% reduction in dementia in women taking HRT from early
menopause and for more than 10 years.26 Other Level III-3
studies, which have not distinguished between early or late
initiation of HRT, have not reported a consistent cognitive benefit.
Stroke
In the WHI, no effect of cHRT on stroke was seen in the first year
of therapy. The risk ratio increased to 1.72 over the next 4 years
and decreased to 0.66 in Year 6. Yearly confidence intervals have
not been published, but, in the older WHI population, the overall
absolute increased risk was 8 per 10 000 women per annum
(0.08%). The final HR for stroke was 1.31 (adjusted 95% CI, 0.93–
1.84).27 In the oestrogen-only arm of the WHI, the HR was 1.39
(adjusted 95% CI, 0.97–1.99).27 Again the prevalence of stroke is
age-dependent and the numbers under age 60 years were small —
too small to test the critical window hypothesis for stroke. An
increased risk of transient ischaemic attacks and strokes must
currently be presumed as likely in women initiating HRT many
years after menopause.
Ovarian cancer
Data from the WHI, observational studies and, recently, the
Million Women Study (Level III-3) show a non-significant increase
in ovarian cancer after 5 years of cHRT, but a significant increase
after 5 years of unopposed oestrogen-only therapy.28,29 The
increased absolute risk in the Million Women Study was estimated
as one in 2500 users of HRT.29 This risk is mostly seen in women
who have had a hysterectomy with ovarian conservation, and have
taken oestrogen for more than 5 years. This group comprises about
8% of HRT users. Tibolone use was not associated with a rise in
ovarian cancer.
Bowel and uterine cancers
In the cHRT arm of the WHI, a small decrease in these cancers was
seen of around 8 per 10 000 women per annum.2 Oestrogen-only
therapy had no effect on bowel cancer in the WHI.18
Menopausal symptom control and quality of life
Symptom control and perceived improved quality of life are the
main reasons for commencing HRT and for the high continuation
rates. Systematic reviews (Level I) show that HRT very efficiently
controls vasomotor symptoms and urogenital symptoms.30,31 In
the WHI, women taking HRT had significantly reduced joint
pains, and these increased on cessation of therapy. Disease-specific
quality-of-life scores improve in women with menopausal symp-
toms who commence HRT, and are related to reductions in
sleeplessness and tiredness and to increased libido.
The media scare after the initial WHI report in 2002 prompted
medical review and cessation of long-term HRT in some users who
had no further indication for its use. However, many more women
inappropriately stopped HRT, or never started therapy, because of
media and medical perception of its risks. Ironically, many women
who experienced menopause after 2002 may have missed a
therapeutic window for cardioprotection, and possible cognitive
benefit, and also suffered unnecessary menopausal symptoms if
they avoided, or their advisors denied them, the option of taking
HRT. Many women have reported that their doctor or their
pharmacist has said that HRT was too dangerous and they should
use non-evidence-based complementary therapies.32
No complementary therapy has a greater effect than the placebo
used in HRT trials.30,33 Some drugs acting on the brain (eg,
selective serotonin reuptake inhibitors) are moderately better than
placebo at reducing vasomotor symptoms.34 So-called “bioidenti-
cal” or “natural” unregistered hormones, individually compounded
in untested doses and combinations, and often titrated using
unvalidated salivary hormone assays, are mostly unassessed for
efficacy or long-term safety.35 They should not be prescribed, and
they exploit a regulatory loop hole that should be closed by the
Therapeutic Goods Administration.
Tibolone
Although not a traditional HRT, tibolone is a steroid with oestro-
genic, progestogenic and androgenic properties. It has been shown
to have a good safety profile in short-term randomised controlled
trials (Level II) with up to 4 years follow-up.36 It is an all-in-one,
single dose, oral postmenopausal therapy, with a moderately
effective action on menopausal and urogenital symptoms, libido
and bone. Its potential lack of breast stimulation makes it a
possible candidate for the treatment of menopausal symptoms in
women with breast cancer. A 4-year placebo-controlled, ran-
domised trial of tibolone in women with breast cancer (LIBERATE)
will be reported later next year. There is a question mark about a
small increased risk of stroke reported in one trial of older women
with osteoporosis, but this result was confounded by unusually
low numbers of strokes in the placebo group. The Million Women
Study showed an association with breast cancer, which may have
been confounded by selection of women with breast cancer for
tibolone therapy. The LIBERATE study should help resolve this
observation.
Conclusion
The latest data on HRT do not warrant the fear and ultra-
conservative edicts issued in 2002. However, there are potential
side effects and risks involved in taking HRT that may be reduced
by tailoring the therapy to individual patients. Emerging data
suggest that side effects are reduced by:
• using lower HRT doses;
• minimising or eliminating systemic progestogens (by use of
intrauterine progestogen delivery systems);
• using non-oral routes in some women; and
• initiating HRT in symptomatic women from near menopause.
HRT can be offered to informed women for as long as they have
debilitating symptoms, but the data are not yet strong enough to
advocate it for chronic disease prevention, except perhaps for
osteoporosis prevention near menopause, with the option of other
effective fracture prevention treatments at a later age.
Systematic reviews of HRT show that the main two start-up side
effects are irregular uterine bleeding (which is normal during the
first few months of cHRT) and breast tenderness when excessive
oestrogen is used.30 Longer-term therapy is appropriate for womenMJA • Volume 186 Number 12 • 18 June 2007 645
VIEWPOINTwith prolonged symptoms who are aware of the potential risks in
their personal circumstances. When HRT is initiated near meno-
pause for symptom control and subsequent improved quality of
life, there are likely to be additional benefits (reduced fracture and
cardiovascular risk, and possibly cognitive benefits) that outweigh
the risks (which are not significantly raised in women under age
60 years). Beyond this age, women can try stopping HRT to see if
their quality of life is maintained without therapy. However, some
women have continuing symptoms into their seventh decade, and
they should not be denied HRT if their therapy and risks are
assessed on an individual basis, and each patient is aware of the
risks.
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